Paris - Delayed Quote • EUR Guerbet SA (GBT.PA) Follow Compare 26.70 +0.10 +(0.38%) At close: January 17 at 5:35:22 PM GMT+1 All News Press Releases SEC Filings All SEC Filings Corporate Changes & Voting Matters Periodic Financial Reports Proxy Statements Tender Offer/Acquisition Reports Offering Registrations Correction: GUERBET : Financial agenda for 2025 Financial agenda for 2025 Villepinte, 13 janvier 2025: Guerbet (FR0000032526 GBT), a global specialist in contrast agents and solutions for medical imaging, is announcing its financial agenda for 2025. Publications calendar 2024 ANNUAL REVENUE February 06, 2025, after trading 2024 ANNUAL RESULTS March 25, 2025, after trading 2025 1st QUARTER REVENUE April 24, 2025, after trading ANNUAL SHAREHOLDERS’ MEETING May 23, 2025 2025 2nd QUARTER REVENUE July 24, 2025, after trading 2025 FIRST HALF RESULT GUERBET : Financial agenda for 2025 Financial agenda for 2025 Villepinte, 31 October 2024: Guerbet (FR0000032526 GBT), a global specialist in contrast agents and solutions for medical imaging, is announcing its financial agenda for 2025. Publications calendar 2024 ANNUAL REVENUE February 06, 2025, after trading 2024 ANNUAL RESULTS March 27, 2025, after trading 2025 1st QUARTER REVENUE April 24, 2025, after trading ANNUAL SHAREHOLDERS’ MEETING May 23, 2025 2025 2nd QUARTER REVENUE July 24, 2025, after trading 2025 FIRST HALF RESULT GUERBET : Revenue at September 30, 2024. Revenue at September 30, 2024 Continued growth momentum 9-month revenue: €620.5m, up 9.6% at CER1 In the third quarter, momentum remained strong (+5.4% at CER), driven by the Americas (+13.1%) and Asia (+8.1%), while performance in EMEA (-2.3%) was once again impacted by the continued implementation of the new supply chain in France 2024 annual targets confirmed Revenue: expected growth of over 9%on a like-for-like basis and at CERProfitability: re-stated EBITDA margin returnedto a higher level GUERBET : H1 2024 results. H1 2024 results Very dynamic business activity H1 revenue: €419.2m, up 11.8% at CER1 A trajectory driven by all activities and geographical areas Solid increase in profitability The restated EBITDA margin2 was 15.4%, compared to 12.7% a year earlierOperating income almost tripled to €30.3m Upward revision of annual guidance Revenue: expected growth of over 9% like-for-like and at CER (>8% previously)Profitability: restated EBITDA margin rate higher than in 2021 (14.4%) Villepinte, 25 September 2 GUERBET : H1 2024 revenue. H1 2024 revenue Half-yearly activity H1 revenue: €419.2m, up 11.8% at CER1, including an acceleration in Q2 (+14.5%)This acceleration was driven by continued catch-up in the Americas, the normalisation of orders in France and MRI sales Annual targets confirmed Revenue: expected growth of over 8% like-for-like and at CERProfitability: restated EBITDA margin rate2 higher than in 2021 (14.4%) Villepinte, 25 July 2024, 5.45 pm: Guerbet (FR0000032526 GBT), a global specialist in contrast agents and s Exploring Undervalued Opportunities on Euronext Paris With Edenred and Two More Stocks As European markets experience a modest uplift, with France's CAC 40 Index seeing a gain of 0.63%, investors are keenly watching for opportunities that might be lurking beneath the surface of broad market movements. In this context, identifying undervalued stocks becomes particularly compelling, offering potential for those looking to invest in assets that may not yet reflect their intrinsic value given the current economic environment. Airbus And Two Additional Stocks Estimated To Be Undervalued On Euronext Paris Amidst a turbulent week for European markets, where political uncertainty and economic indicators painted a mixed picture, investors are keenly observing potential opportunities. In this context, identifying undervalued stocks such as Airbus on the Euronext Paris could be particularly intriguing for those looking to capitalize on discrepancies between current market prices and intrinsic values. Guerbet : Hugues Lecat appointed Chairman of the Board of Directors of Guerbet. Hugues Lecat appointed Chairman of the Board of Directors of Guerbet Villepinte, 24 May 2024: Guerbet (FR0000032526 GBT), a global specialist in contrast products and solutions for medical imaging, is announcing the appointment of Hugues Lecat as Chairman of the Board of Directors, in accordance with the previously announced timetable (press release of 20 March 2024). Following the approval of his appointment as director at the Annual General Meeting held today at the registered office, the Boar Guerbet : NUCLIDIUM and Guerbet Form Strategic Partnership to Support the Advancement of targeted Copper-based Radiotheranostics. NUCLIDIUM and Guerbet Form Strategic Partnership to Support the Advancement of targeted Copper-based Radiotheranostics -- Agreement brings together Guerbet’s industry leading expertise in medical imaging technologies, production, and commercialization with Nuclidium’s in depth know-how of the copper radioisotope production and theranostic development -- Basel, Switzerland and Villepinte, France, May 22, 2024 – NUCLIDIUM and Guerbet (GBT) today announced a strategic partnership to advance NUCLIDI Guerbet : Q1 2024 revenue. Q1 2024 revenue Quarterly activity Revenue: €194.3m, up 8.8% at CER1Growth remains particularly strong in Asia (+26.8% at CER) and the Americas (+20.1% at CER); the EMEA region (-6.2% at CER) was temporarily impacted by the reform of the supply of contrast products in France Annual targets confirmed Revenue: expected growth of over 8% like-for-like and at CERProfitability: restated EBITDA margin rate2 higher than in 2021 (14.4%) Villepinte, 25 April 2024, 5.45 pm: Guerbet (FR0000032526 GBT), a g Performance Overview Trailing total returns as of 1/17/2025, which may include dividends or other distributions. Benchmark is CAC 40 Return GBT.PA CAC 40 YTD +0.75% +5.42% 1-Year +48.17% +4.21% 3-Year -17.87% +7.93%